Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid ...

Absci is developing ABS-101, an anti-TL1A antibody with potential in ulcerative colitis, Crohn's disease, and other ...

“The words used in these conversations with ultrasound technicians or obstetric sonographers — whom we consider experts on ...

UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals. The company is also exploring translational and commercial ...

Overseas Equity ETF posted a return of 8.45% in the second quarter of 2025. All regions contributed to performance; developed ...

Unclaimed funds are exactly what they sound like: Money that’s rightfully yours but somehow got lost in the shuffle. Think ...

For many parents, their first thoughts and images of their unborn child begin with the first ultrasound image they see. New studies suggest those thoughts are measurably influenced by how the ...

High responses maintained over four years in nearly half of patients: 48.9% of Week 16 PASI 0 responders sustained complete ski ...

As we continue to observe National Recovery Month, Homeland Security Today contributor Robert Patterson – former Acting ...

Josephine Carmela Auciello is redefining what it means to lead as a woman in 2025. As an award-winning Feminine Leadership ...

HTL0039732 (also known as NXE0039732) is Nxera's novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK's Centr ...

GERMANTOWN, MD / ACCESS Newswire / September 17, 2025 / uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, today announced the launch of its 2nd-Generation iPSC ...